Eptifibatide API Manufacturers

Looking for Eptifibatide API 188627-80-7?

Description:

Here you will find a list of producers, manufacturers and distributors of Eptifibatide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Eptifibatide 

Synonyms:

Integrelin , Intrifiban  

Cas Number:

188627-80-7 

DrugBank number:

DB00063 

Unique Ingredient Identifier:

NA8320J834

Eptifibatide is a type of Glycoprotein IIb/IIIa receptor antagonists

Glycoprotein IIb/IIIa receptor antagonists belong to a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the field of medicine. These antagonists specifically target and inhibit the activity of the glycoprotein IIb/IIIa receptors found on platelets.

The glycoprotein IIb/IIIa receptors play a crucial role in platelet aggregation, which is an essential step in the formation of blood clots. By blocking these receptors, glycoprotein IIb/IIIa receptor antagonists prevent platelets from binding to each other and forming clots, thereby inhibiting thrombus formation.

These pharmaceutical compounds have shown great potential in the treatment and prevention of conditions related to unwanted blood clotting, such as acute coronary syndromes and percutaneous coronary interventions. They are commonly used during angioplasty and stent placement procedures to reduce the risk of clot formation and subsequent complications.

Glycoprotein IIb/IIIa receptor antagonists are typically administered intravenously and have a relatively short duration of action. Common examples include abciximab, eptifibatide, and tirofiban. These agents are carefully monitored and controlled due to their potent antiplatelet effects.

It is important to note that the use of glycoprotein IIb/IIIa receptor antagonists requires close medical supervision, as they can increase the risk of bleeding. Therefore, healthcare professionals must carefully weigh the benefits and risks when considering the administration of these pharmaceutical APIs.

Eptifibatide (Glycoprotein IIb/IIIa receptor antagonists), classified under Anticoagulants

Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.

There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.

Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.

While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.

In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.

• Xi'an Tian Guangyuan Biotech Co.,Ltd from China, product country of origin China
• Shandong Octagon Chemicals Limited from China, product country of origin China
• Sinoway industrial Co.,Ltd from China, product country of origin China
• Hainan Shuangcheng from China, product country of origin China
• Chemi S.p.A. from Italy, product country of origin Italy
• AMBIOPHARM from United States, product country of origin Unknown
• Wuxi Kaili  from China, product country of origin China
• ALP PHARM from China, product country of origin China
• USV from India, product country of origin India
• Flavine from Germany, product country of origin Unknown
• Hybio Pharmaceutical from China, product country of origin China
• Teva API from Israel, product country of origin Unknown
• Corden Pharma from Germany, product country of origin Belgium
• Polypeptide Labs from Sweden, product country of origin Unknown
• Sun Pharma from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.